Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Fennec Pharmaceuticals Inc. (FENC)

9.61   0.1 (1.05%) 11-28 16:00
Open: 9.55 Pre. Close: 9.51
High: 9.88 Low: 9.12
Volume: 70,619 Market Cap: 252(M)

Technical analysis

as of: 2022-11-28 4:39:44 PM
Overall:       
Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 11.53     One year: 13.47
Support: Support1: 8.52    Support2: 7.69
Resistance: Resistance1: 9.88    Resistance2: 11.53
Pivot: 8.61
Moving Average: MA(5): 9.37     MA(20): 8.57
MA(100): 7.47     MA(250): 6.16
MACD: MACD(12,26): 0.3     Signal(9): 0.2
Stochastic oscillator: %K(14,3): 84.8     %D(3): 86.7
RSI: RSI(14): 72.9
52-week: High: 9.88  Low: 3.96
Average Vol(K): 3-Month: 164 (K)  10-Days: 115 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ FENC ] has closed below upper band by 8.4%. Bollinger Bands are 103.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 9.89 - 9.93 9.93 - 9.96
Low: 9.03 - 9.07 9.07 - 9.11
Close: 9.54 - 9.61 9.61 - 9.67

Company Description

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Headline News

Thu, 24 Nov 2022
Taiwanese textile giant behind FIFA jerseys made from recycled marine debris - Taiwan News

Tue, 22 Nov 2022
Expert Ratings for Fennec Pharmaceuticals - Fennec Pharmaceuticals (NASDAQ:FENC) - Benzinga

Tue, 22 Nov 2022
How Will the Market React to Fennec Pharmaceuticals Inc (FENC) Stock Getting a Bullish Rating - InvestorsObserver

Wed, 16 Nov 2022
Reports of children not attending school: Kumar - FBC News

Mon, 14 Nov 2022
Textile firms bet on World Cup - 台北時報

Mon, 14 Nov 2022
Fennec Pharmaceuticals Inc (NASDAQ:FENC) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 26 (M)
Shares Float 22 (M)
% Held by Insiders 17.2 (%)
% Held by Institutions 43.5 (%)
Shares Short 547 (K)
Shares Short P.Month 498 (K)

Stock Financials

EPS -0.63
EPS Est Next Qtl 0
EPS Est This Year -0.24
EPS Est Next Year -0.21
Book Value (p.s.) 0.1
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -45.8
Return on Equity (ttm) -195.2
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)

Stock Valuations

PE Ratio -15.26
PEG Ratio 0
Price to Book value 87.36
Price to Sales 0
Price to Cash Flow 0

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.